Por favor, use este identificador para citar o enlazar este ítem:
http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/7498| Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomised controlled trial | |
| Fergus Hamilton Todd Lee David Arnold Richard Lilford karla hemming | |
| Acceso Abierto | |
| Atribución-NoComercial | |
| 10.1016/j.ijid.2021.06.034 | |
| https://www.medrxiv.org/content/10.1101/2021.04.01.21254679v1 | |
| Introduction Randomised trials are generally performed from a frequentist perspective reporting point estimates and 95% confidence intervals. This approach can confuse “evidence of no effect” with “no evidence of an effect” and does not allow for contextual knowledge. The RECOVERY trial evaluated convalescent plasma for patients hospitalised with COVID-19, the interaction test for the primary outcome was not statistically significant, and the trial concluded no evidence of an effect. From the clinical immunology perspective, there is strong justification to expect differential responses to convalescent plasma in patients who already have their own antibodies to SARS-CoV2 (seropositive) versus those who do not (seronegative). | |
| medRxiv and bioRxiv | |
| 05-04-2021 | |
| Artículo | |
| www.medrxiv.org | |
| Inglés | |
| Epidemia COVID-19 | |
| Público en general | |
| VIRUS RESPIRATORIOS | |
| Versión publicada | |
| publishedVersion - Versión publicada | |
| Aparece en las colecciones: | Artículos científicos |
Cargar archivos:
| Fichero | Tamaño | Formato | |
|---|---|---|---|
| Is Covalescent plasma futile in COVID 19_ A Bayesian re anaylisis of the RECOVERY randomised controlled trial.pdf | 159.26 kB | Adobe PDF | Visualizar/Abrir |